ALUMIS INC (ALMS) — insider trading
Health Care · NASDAQ
ALUMIS INC (ALMS) has 43 reported SEC Form 4 insider transactions in our data, including 4 open-market purchases and 9 open-market sales among the most recent 43 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Open-market purchase | 273,290 | $10.63 | $2.90M | Form 4 |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Open-market purchase | 273,291 | $10.63 | $2.90M | Form 4 |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Open-market sale | 48,065 | $10.55 | $507.0K | Form 4 |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Open-market sale | 48,066 | $10.55 | $507.0K | Form 4 |
| 2026-09-04 | AKKARAJU SRINIVAS | Director | Open-market purchase | 220,070 | $11.17 | $2.46M | Form 4 |
| 2026-09-04 | AKKARAJU SRINIVAS | Director | Open-market purchase | 220,070 | $11.17 | $2.46M | Form 4 |
| 2026-08-03 | Bradley Mark Christopher | Officer (Chief Development Officer) | Open-market sale | 2,572 | $26.37 | $67.8K | Form 4 |
| 2026-08-03 | Drappa Jorn | Officer (Chief Medical Officer) | Open-market sale | 2,447 | $26.37 | $64.5K | Form 4 |
| 2026-08-03 | Goldstein David M | Officer (Chief Scientific Officer) | Open-market sale | 2,596 | $26.37 | $68.5K | Form 4 |
| 2026-08-03 | Hardiman Roy C. | Officer (Chief Business & Strategy Ofcr) | Open-market sale | 2,692 | $26.37 | $71.0K | Form 4 |
| 2026-08-03 | Pangali Sanam | Officer (Chief Legal Officer) | Open-market sale | 1,364 | $26.37 | $36.0K | Form 4 |
| 2026-08-03 | Schroer John R. | Officer (Chief Financial Officer) | Open-market sale | 3,282 | $26.37 | $86.5K | Form 4 |
| 2026-07-06 | Pangali Sanam | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-07-06 | Pangali Sanam | Officer (Chief Legal Officer) | Open-market sale | 5,000 | $28.00 | $140.0K | Form 4 |
| 2026-07-06 | Pangali Sanam | Officer (Chief Legal Officer) | Option exercise / conversion | 5,000 | $5.06 | $25.3K | Form 4 |
| 2026-06-30 | AKKARAJU SRINIVAS | Director | Grant / award / vesting (derivative) | 15,528 | — | $0 | Form 4 |
| 2026-06-30 | AKKARAJU SRINIVAS | Director | Grant / award / vesting | 3,553 | — | $0 | Form 4 |
| 2026-06-30 | Machado Patrick | Director | Grant / award / vesting (derivative) | 15,528 | — | $0 | Form 4 |
| 2026-06-30 | Machado Patrick | Director | Grant / award / vesting | 3,553 | — | $0 | Form 4 |
| 2026-06-30 | Srivastava Sapna | Director | Grant / award / vesting (derivative) | 15,528 | — | $0 | Form 4 |
| 2026-06-30 | Srivastava Sapna | Director | Grant / award / vesting | 3,553 | — | $0 | Form 4 |
| 2026-06-30 | Yao Zhengbin | Director | Grant / award / vesting (derivative) | 15,528 | — | $0 | Form 4 |
| 2026-06-30 | Yao Zhengbin | Director | Grant / award / vesting | 3,553 | — | $0 | Form 4 |
| 2026-06-30 | TETRAULT LYNN A. | Director | Grant / award / vesting (derivative) | 15,528 | — | $0 | Form 4 |
| 2026-06-30 | TETRAULT LYNN A. | Director | Grant / award / vesting | 3,553 | — | $0 | Form 4 |
| 2026-05-22 | Drappa Jorn | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 15,535 | — | $0 | Form 4 |
| 2026-05-22 | Drappa Jorn | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 11,317 | — | $0 | Form 4 |
| 2026-05-22 | Drappa Jorn | Officer (Chief Medical Officer) | Option exercise / conversion | 15,535 | $5.06 | $78.6K | Form 4 |
| 2026-05-22 | Drappa Jorn | Officer (Chief Medical Officer) | Option exercise / conversion | 11,317 | $8.84 | $100.0K | Form 4 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | Other acquisition or disposition | 680,486 | — | $0 | Form 4 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | Other acquisition or disposition | 1,176,470 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Capital Management VI LLC; Foresite Capital Management V, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Fund VI LP; Labs Co-Invest V, LLC; Foresite Labs Management I, LLC; Foresite Labs Fund I, L.P. | 10% owner | Other acquisition or disposition | 680,486 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Capital Management VI LLC; Foresite Capital Management V, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Fund VI LP; Labs Co-Invest V, LLC; Foresite Labs Management I, LLC; Foresite Labs Fund I, L.P. | 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Capital Management VI LLC; Foresite Capital Management V, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Fund VI LP; Labs Co-Invest V, LLC; Foresite Labs Management I, LLC; Foresite Labs Fund I, L.P. | 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Capital Management VI LLC; Foresite Capital Management V, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Fund VI LP; Labs Co-Invest V, LLC; Foresite Labs Management I, LLC; Foresite Labs Fund I, L.P. | 10% owner | Other acquisition or disposition | 1,176,470 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Labs, LLC; Foresite Labs Affiliates 2021, LLC | 10% owner | Other acquisition or disposition | 680,486 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Labs, LLC; Foresite Labs Affiliates 2021, LLC | 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Labs, LLC; Foresite Labs Affiliates 2021, LLC | 10% owner | Other acquisition or disposition | 1,123,337 | — | $0 | Form 4 |
| 2026-04-01 | Foresite Labs, LLC; Foresite Labs Affiliates 2021, LLC | 10% owner | Other acquisition or disposition | 1,176,470 | — | $0 | Form 4 |
| 2026-01-26 | Pangali Sanam | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 186,200 | — | $0 | Form 4 |
| 2025-09-25 | Goldstein David M | Officer (Chief Scientific Officer) | Acquisition/disposition by will or descent | 1,000 | — | $0 | Form 5 |
Ask the chat about ALMS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ALUMIS INC (ALMS).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.